These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39115241)

  • 1. Kinetic Trajectories of Glucose Uptake in Single Cancer Cells Reveal a Drug-Induced Cell-State Change Within Hours of Drug Treatment.
    Kim J; Ng RH; Liang J; Johnson D; Shin YS; Chatziioannou AF; Phelps ME; Wei W; Levine RD; Heath JR
    J Phys Chem B; 2024 Aug; 128(33):7978-7986. PubMed ID: 39115241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Glycolytic Response to Multiple Classes of Anti-glioblastoma Drugs by Noninvasive Measurement of Pyruvate Kinase M2 Using [
    Beinat C; Patel CB; Xie Y; Gambhir SS
    Mol Imaging Biol; 2020 Feb; 22(1):124-133. PubMed ID: 30989436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.
    McKinney A; Lindberg OR; Engler JR; Chen KY; Kumar A; Gong H; Lu KV; Simonds EF; Cloughesy TF; Liau LM; Prados M; Bollen AW; Berger MS; Shieh JTC; James CD; Nicolaides TP; Yong WH; Lai A; Hegi ME; Weiss WA; Phillips JJ
    Mol Cancer Ther; 2019 Sep; 18(9):1565-1576. PubMed ID: 31270152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal transition and increased therapy resistance of glioblastoma cells is related to astrocyte reactivity.
    Niklasson M; Bergström T; Jarvius M; Sundström A; Nyberg F; Haglund C; Larsson R; Westermark B; Segerman B; Segerman A
    J Pathol; 2019 Nov; 249(3):295-307. PubMed ID: 31298733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High density is a property of slow-cycling and treatment-resistant human glioblastoma cells.
    Sabelström H; Quigley DA; Fenster T; Foster DJ; Fuchshuber CAM; Saxena S; Yuan E; Li N; Paterno F; Phillips JJ; James CD; Norling B; Berger MS; Persson AI
    Exp Cell Res; 2019 May; 378(1):76-86. PubMed ID: 30844389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
    Ramis G; Villalonga-Planells R; Serra-Sitjar M; Brell M; Fernández de Mattos S; Villalonga P
    Cell Oncol (Dordr); 2019 Aug; 42(4):521-536. PubMed ID: 30980364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamer-Conjugated Gold Nanoparticles Targeting Epidermal Growth Factor Receptor Variant III for the Treatment of Glioblastoma.
    Peng L; Liang Y; Zhong X; Liang Z; Tian Y; Li S; Liang J; Wang R; Zhong Y; Shi Y; Zhang X
    Int J Nanomedicine; 2020; 15():1363-1372. PubMed ID: 32184591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
    Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
    Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
    Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
    Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Compounds That Decrease Glioblastoma Growth and Glucose Uptake in Vitro.
    Landis CJ; Zhang S; Benavides GA; Scott SE; Li Y; Redmann M; Tran AN; Otamias A; Darley-Usmar V; Napierala M; Zhang J; Augelli-Szafran CE; Zhang W; Hjelmeland AB
    ACS Chem Biol; 2018 Aug; 13(8):2048-2057. PubMed ID: 29905460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
    Eller JL; Longo SL; Hicklin DJ; Canute GW
    Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
    Taylor TE; Furnari FB; Cavenee WK
    Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
    Bi J; Khan A; Tang J; Armando AM; Wu S; Zhang W; Gimple RC; Reed A; Jing H; Koga T; Wong IT; Gu Y; Miki S; Yang H; Prager B; Curtis EJ; Wainwright DA; Furnari FB; Rich JN; Cloughesy TF; Kornblum HI; Quehenberger O; Rzhetsky A; Cravatt BF; Mischel PS
    Cell Rep; 2021 Nov; 37(5):109957. PubMed ID: 34731610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.
    Pedron S; Wolter GL; Chen JE; Laken SE; Sarkaria JN; Harley BAC
    Biomaterials; 2019 Oct; 219():119371. PubMed ID: 31352310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
    Banstola A; Duwa R; Emami F; Jeong JH; Yook S
    Mol Pharm; 2020 Nov; 17(11):4386-4400. PubMed ID: 33079558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
    Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R
    J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.
    Stockhausen MT; Kristoffersen K; Stobbe L; Poulsen HS
    Cancer Biol Ther; 2014 Feb; 15(2):216-24. PubMed ID: 24525857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
    PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A heat shock protein 90 inhibitor reduces oncoprotein expression and induces cell death in heterogeneous glioblastoma cells with EGFR, PDGFRA, CDK4, and NF1 aberrations.
    Ho KT; Chen PF; Chuang JY; Gean PW; Hsueh YS
    Life Sci; 2022 Jan; 288():120176. PubMed ID: 34848192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
    Pinheiro KV; Thomaz A; Souza BK; Metcalfe VA; Freire NH; Brunetto AT; de Farias CB; Jaeger M; Bambini V; Smith CGS; Shaw L; Roesler R
    Mol Biol Rep; 2020 Sep; 47(9):6817-6828. PubMed ID: 32862352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.